This page shows the latest lonafarnib news and features for those working in and with pharma, biotech and healthcare.
It doubled its phase III anticancer portfolio, with Novacea's high-dose capsule formulation of calcitriol, DN-101 (Asentar), joining its farnesyl protein transferase inhibitor lonafarnib (Sarasar) at the market end
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Ground-breaking results for lonafarnib. Lonafarnib (Sarasar) is an orally active FTI under clinical development with Schering-Plough (now Merck &Co) in capsule formulation for the treatment of progeria and various ... Lonafarnib and FTIs as a class have
More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.
Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...